B+
Bull case
25%
Probability
Target price
$37.69
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
GMAB
Genmab A/SFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
DARZALEX worldwide net sales reached $4.207 billion in Q2 2026, supporting Genmab’s royalty engine, while the European TEPKINLY approval and positive DLBCL-4 PFS result broaden epcoritamab’s opportunity set. [#PR-EARNINGS-2026-07-15] [#IR-GMAB-TEPKINLY-2026-07-06]
Posture
Defensive
Lead driver
Value
What changed
9 setup hits (3d) with net bullish as of 2026-10-28.
What can break
Analyst revisions, consensus surprise data, short interest, options data, and post-event price attribution are unavailable in the packet.
Momentum
98
Value
61
Sentiment
6
Setup hits (3d)
9 · Net Bullish
AI TargetsBase $29.02 · Bull $37.69 · Bear $24.67Analysis 2026-08-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $48.75
Why
Momentum98 · Δ7d +0.5
Value61 · Δ7d -0.7
Sentiment6 · Δ7d -10.3
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 9 setup hits (3d) with net bullish as of 2026-10-28.
- • Value remains the lead driver in the composite, 7D delta -0.7.
Contradictions & invalidation
- • Analyst revisions, consensus surprise data, short interest, options data, and post-event price attribution are unavailable in the packet.
- • EPCORE DLBCL-1 did not meet its U.S. overall-survival primary endpoint. [#IR-GMAB-DLBCL1-2026-07-23]
- • The DLBCL-1 U.S.
Catalyst clock
2026-06-29
DLBCL-4 regulatory and commercial follow-through
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendImproving
Δ7d
+0.5
Δ21d
+5.5
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-1.5
Sentiment
6
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.3
Δ21d
-17.3
Why this grade
Composite grade F. Momentum 98.3 / Value 61.3 / Sentiment 6.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$29.02
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.67
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$26.67B
Beta
0.76
Shares Out
597.54M
P/E (TTM)
13.4
P/S (TTM)
5.65
P/FCF (TTM)
16.83
Rev YoY
+23.0%
EPS YoY
-10.9%
Gross Margin
+93.0%
Op Margin
+32.3%
Net Debt
$3.71B
Current Ratio
2.46
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data